Invention:
This innovation is a novel method of treating cardiovascular disease, specifically, the continued tissue damage that occurs during myocardial ischemic reperfusion injury (MIRI) elicited by myocardial ischemia. While damage during MIRI is multifaceted, this new treatment addresses nearly every caveat including reactive oxygen species (ROS), calcium overload, and multiple inflammatory responses. Studies completed by the innovators have shown that the PNA5 treatment reduced infarct size by 35.02% compared to the control-treated animals, decreased regional fibrosis compared to control-treated mice, and preserved heart function.
Background:
While reperfusion therapies are required to address myocardial ischemia successfully, the continued tissue damage that occurs during myocardial ischemic reperfusion injury (MIRI) can negatively impact the recovery of the heart’s structure and function. The treatment of choice for reducing acute myocardial ischemic injury and limiting MI size is timely and effective myocardial reperfusion using either thrombolytic therapy or primary percutaneous coronary intervention (PPCI). However, the process of reperfusion can itself induce cardiomyocyte death, known as myocardial reperfusion injury, for which there is still no effective therapy.
Applications:
- Cardiovascular disease
- Cardiovascular inflammation
- Brain inflammation
Advantages:
- Novel approach to an otherwise untapped area of research
- Animal studies conducted with statistically significant results
- Multi-faceted treatment
- Improved half-life
- Reduced infarct size
- Decreased fibrosis
- Preservation of heart function
